InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting
CompanyDrug

InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting

Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery
Company

Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery

Sichuan Biokin Pharmaceutical Plans RMB3.9 Billion Private Placement for Novel Drug R&D
CompanyDeals

Sichuan Biokin Pharmaceutical Plans RMB3.9 Billion Private Placement for Novel Drug R&D

LiteDD's LIT0922 Approved for Phase I Trial in Marker-Expressing Advanced Solid Tumors
CompanyDrug

LiteDD’s LIT0922 Approved for Phase I Trial in Marker-Expressing Advanced Solid Tumors

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4602 Clinical Study in Advanced Solid Tumors
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4602 Clinical Study in Advanced Solid Tumors

Jiangsu Cowin Biotech Obtains NMPA License for Gene Methylation Detection Kit
CompanyMedical Device

Jiangsu Cowin Biotech Obtains NMPA License for Gene Methylation Detection Kit

InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment
CompanyDrug

InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment

Bristol-Myers Squibb's Opdivo/Yervoy Combo Approved by EU for Hepatocellular Carcinoma
CompanyDrug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved by EU for Hepatocellular Carcinoma

Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development
CompanyDeals

Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development

Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion
CompanyDeals

Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion

AbbVie's Skyrizi Approved by China's NMPA for Moderate to Severe Crohn's Disease
CompanyDrug

AbbVie’s Skyrizi Approved by China’s NMPA for Moderate to Severe Crohn’s Disease

Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy
CompanyDeals

Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy